Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

The US FDA has approved the drug Mitapivat, marketed as Aqvesme, as the very first oral therapy for anemia in adults with ...

The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks ...

CRISPR/Cas9 gene-editing therapy is a groundbreaking technology that enables highly precise modification of disease-causing ...

The US Food and Drug Administration’s (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks ...

The US FDA has greenlit Mitapivat, the first oral treatment for anaemia in adults with thalassemia, marking a significant advancement in thalassemia care.

Kavita Mehta suffers from beta thalassaemia, a genetic condition preventing her body from producing sufficient haemoglobin ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

A woman who has received a breakthrough gene-editing treatment on the NHS is hoping 2026 is the year she will be cured of a ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...